The secondary increase in EPO levels can be explained by the fact that all Chuvash polycythemia-associated VHL gene variants have been shown to exhibit decreased protein stability and reduced binding of the Hypoxia-inducible factor 1 (HIF1) protein, thereby disturbing the physiological sensing of cellular hypoxia [15, 16]. This evidence concerns the gene EPO and polycythemia.